NextCure (NASDAQ:NXTC) Major Shareholder Adar1 Capital Management, Llc Purchases 3,662 Shares of Company Stock

NextCure, Inc. (NASDAQ:NXTC) major shareholder Adar1 Capital Management, Llc bought 3,662 shares of NextCure stock in a transaction on Friday, November 6th. The shares were acquired at an average cost of $5.10 per share, for a total transaction of $18,676.20. Following the completion of the acquisition, the insider directly owned 737,956 shares in the company, valued at approximately $3,763,575.60. The trade was a 0.50% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Adar1 Capital Management, Llc also recently made the following trade(s):

• On Thursday, November 5th, Adar1 Capital Management, Llc purchased 1,024 shares of NextCure stock. The shares were acquired at an average cost of $5.10 per share, with a total value of $5,222.40.
• On Tuesday, October 27th, Adar1 Capital Management, Llc purchased 3,553 shares of NextCure stock. The shares were acquired at an average price of $5.10 per share, for a total transaction of $18,120.30.
• On Monday, October 26th, Adar1 Capital Management, Llc purchased 1,672 shares of NextCure stock. The shares were acquired at an average price of $5.03 per share, for a total transaction of $8,410.16.
• On Friday, October 23rd, Adar1 Capital Management, Llc acquired 5,626 shares of NextCure stock. The stock was acquired at an average cost of $4.83 per share, for a total transaction of $27,173.58.

NextCure Stock Up 17.6%

NASDAQ NXTC opened at $6.27 on Tuesday. The company has a market capitalization of $22.63 million, a price-to-earnings ratio of -0.72 and a beta of 1.22. NextCure, Inc. has a twelve month low of $1.55 and a twelve month high of $15.74. The stock has a fifty day simple moving average of $6.06 and a 200 day simple moving average of $7.67.

Hedge Funds Weigh In On NextCure

An institutional investor recently raised its position in NextCure stock. Renaissance Technologies LLC boosted its position in NextCure, Inc. (NASDAQ:NXTC) by 80.0% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 60,534 shares of the company’s stock after buying an additional 26,900 shares during the quarter. Renaissance Technologies LLC owned approximately 1.68% of NextCure worth $647,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 42.65% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently weighed in on NXTC shares. Weiss Ratings lowered shares of NextCure from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, October 26th. Wall Street Zen raised NextCure from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. Finally, HC Wainwright reissued a “buy” rating on shares of NextCure in a research report on Thursday, August 13th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $20.00.

About NextCure

NextCure, Inc (NASDAQ: NXTC) is a clinical-stage biotechnology company focused on developing immunomedicines for the treatment of cancer. The company’s research is aimed at identifying and targeting biological mechanisms that suppress the immune system’s ability to recognize and attack tumor cells.

NextCure’s product candidates have included NC318, an antibody designed to target Siglec-6, and NC410, a fusion protein intended to block the LAIR-1 immune-suppressive pathway. These programs have been evaluated in early-stage clinical studies involving patients with advanced solid tumors, with the goal of developing treatments that may restore or enhance anti-tumor immune responses.

Founded in 2015 and headquartered in the United States, NextCure has operated primarily as a research and development company serving the global oncology market through clinical trials and collaborations.